文献速递产科母胎医学

低分子肝素治疗早发性胎儿生长受限不能延长妊娠:一项随机临床试验

Treatment of early-onset fetal growth restriction with low molecular weight heparin does not prolong gestation: a randomized clinical trial.
PubMed 文献 · Am J Obstet Gynecol · 2024-11-07

这项在西班牙2所大学医院开展的III期、多中心、三盲、平行组随机临床试验,纳入49例早发性胎盘胎儿生长受限单胎妊娠,比较诊断时开始预防剂量贝米肝素与安慰剂的效果。结果显示,低分子肝素组妊娠延长中位数42天 vs 安慰剂组41.5天(中位差0.5天,95%CI -22.7至6.3,P=.667),分娩时中位孕周35.1周 vs 34.6周(中位差0.5周,95%CI -3.4至1.2,P=.639),均无显著差异。

要点

  • 早发性胎儿生长受限诊断时开始预防剂量低分子肝素未延长妊娠。
  • 低分子肝素组妊娠延长中位数42天 vs 安慰剂组41.5天,差异无统计学意义。
  • 低分子肝素组分娩中位孕周35.1周 vs 安慰剂组34.6周,差异无统计学意义。

核心结论

  • 在早发性胎儿生长受限个体中,诊断时开始预防剂量低分子肝素不能延长妊娠。

研究设计与样本

  • III期、多中心、三盲、平行组随机临床试验,在西班牙2所大学医院开展。
  • 纳入符合adapted Delphi共识的早发性胎盘胎儿生长受限单胎妊娠,共49例(低分子肝素组23例,安慰剂组26例)。
  • 干预为皮下贝米肝素3500 IU/0.2 mL/d或安慰剂,从诊断纳入时至分娩。
  • 主要结局为从纳入至活产的妊娠延长天数及活产时孕周天数。

主要发现

  • 低分子肝素组妊娠延长中位数42天 vs 安慰剂组41.5天(中位差0.5天,95%CI -22.7至6.3,P=.667)。
  • 低分子肝素组分娩中位孕周35.1周 vs 安慰剂组34.6周(中位差0.5周,95%CI -3.4至1.2,P=.639)。

关键数值与推荐

  • 早发性胎盘胎儿生长受限诊断标准:诊断孕周20+0至31+6周,脐动脉多普勒舒张期血流缺失/反向;或估计胎儿体重<第10百分位且脐动脉多普勒搏动指数>第95百分位;或估计胎儿体重<第10百分位且子宫动脉多普勒平均搏动指数>第95百分位。
  • 贝米肝素剂量:3500 IU/0.2 mL/d,皮下注射。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although there is a biological basis for it, there is scarce evidence on the effect of heparin in ameliorating placental insufficiency and maximizing gestational age at delivery among fetal growth restriction pregnancies. OBJECTIVE: To explore the effectiveness of treatment using low molecular weight heparin at a prophylactic dose started at the time of diagnosis in prolonging gestation in pregnancies with early-onset fetal growth restriction. STUDY DESIGN: This was a phase III, multicenter, triple-blind, parallel-arm randomized clinical trial conducted in 2 university hospitals in Spain. Singleton pregnancies qualifying for early-onset placental FGR according to the adapted Delphi consensus (20+0-31+6 weeks at diagnosis with umbilical artery Doppler with absent/reversed diastolic flow; or estimated fetal weight <10th percentile plus pulsatility index of umbilical artery Doppler >95th percentile; or estimated fetal weight <10th percentile plus mean pulsatility index of uterine artery Doppler >95th) were randomized to receive either subcutaneous treatment with bemiparin 3500 IU/0.2 mL/d or a placebo from inclusion at diagnosis to the time of delivery. The primary outcomes were prolongation of pregnancy from inclusion to live birth (days) and gestational age at live birth (days). RESULTS: Forty-nine patients were included (23 in the low molecular weight heparin group and 26 in the placebo group). In the low molecular weight heparin group, the median prolongation of pregnancy was 42 days, while in the placebo group it was 41.5 days (median difference 0.5 days [95% confidence interval -22.7 to 6.3] (P=.667)) and in the low molecular weight heparin group, the median gestational age at delivery was 35.1 weeks, while in the placebo group, it was 34.6 weeks (median difference 0.5 weeks [95% confidence interval -3.4 to 1.2] (P=.639)). CONCLUSION: The use of prophylactic dose low molecular weight heparin started at the time of diagnosis does not prolong pregnancy in individuals with early-onset fetal restriction.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. González A, Peguero A, Meler E, et al. Treatment of early-onset fetal growth restriction with low molecular weight heparin does not prolong gestation: a randomized clinical trial. Am J Obstet Gynecol. 2024. PMID: 39521297. doi:10.1016/j.ajog.2024.10.055

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。